benzoxazoles has been researched along with Parkinson Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, GC; Burlein, C; Cosden, M; Drolet, RE; Flick, R; Fraley, M; Gretzula, CA; Hatcher, NG; Jinn, S; Kandebo, M; Lemaire, W; Ma, L; Marcus, JN; Minnick, C; Mulhearn, J; Smith, SM; Toolan, D; Watt, ML; Yao, L | 1 |
| Chen, AQ; Chen, H; Chen, L; Chen, WF; Chen, XY; Liu, HX; Liu, HY; Pang, YY; Sheng, Q; Wang, Y; Xue, Y; Yang, YT | 1 |
| Bronzova, J; Hauser, RA; Lang, AE; Rascol, O; Sampaio, C; Theeuwes, A; van de Witte, SV | 2 |
| Bronzova, J; Hauser, RA; Lang, AE; Rascol, O; Sampaio, C; Theeuwes, AA; van de Witte, SV | 1 |
| Bronzova, J; Ferreira, JJ; Goetz, CG; Stebbins, GT; Stocchi, F; Theeuwes, A; van de Witte, S | 1 |
| Wolf, WA | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Feenstra, RW; Glennon, JC; Hesselink, MB; Long, SK; McCreary, AC; Reinders, JH; Ronken, E; Van Der Neut, M; Van Scharrenburg, G | 1 |
1 review(s) available for benzoxazoles and Parkinson Disease
| Article | Year |
|---|---|
SLV-308. Solvay.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Clinical Trials as Topic; Drugs, Investigational; Humans; Parkinson Disease; Piperazines; Technology, Pharmaceutical | 2003 |
4 trial(s) available for benzoxazoles and Parkinson Disease
| Article | Year |
|---|---|
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.
Topics: Aged; Benzoxazoles; Chemotherapy, Adjuvant; Dopamine Agonists; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Piperazines; Treatment Outcome | 2009 |
Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
Topics: Aged; Antiparasitic Agents; Benzoxazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Piperazines; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Temporal stability of the Unified Dyskinesia Rating Scale.
Topics: Aged; Benzothiazoles; Benzoxazoles; Disability Evaluation; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Neurologic Examination; Observer Variation; Parkinson Disease; Piperazines; Pramipexole; Reproducibility of Results; Videotape Recording | 2011 |
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
Topics: Adult; Aged; Antiparkinson Agents; Benzoxazoles; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Piperazines; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
4 other study(ies) available for benzoxazoles and Parkinson Disease
| Article | Year |
|---|---|
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Topics: alpha-Synuclein; Animals; Benzoxazoles; Dopaminergic Neurons; Glucosylceramidase; Glucosyltransferases; Glycosphingolipids; In Vitro Techniques; Lysosomes; Mice; Neurons; Parkinson Disease; Primary Cell Culture; Protein Aggregates; Rats; Synucleinopathies | 2021 |
Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats.
Topics: Action Potentials; Animals; Benzoxazoles; Globus Pallidus; Haloperidol; Male; Naphthyridines; Neurons; Orexin Receptor Antagonists; Orexin Receptors; Orexins; Oxidopamine; Parkinson Disease; Postural Balance; Rats; Rats, Wistar; Urea | 2016 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Topics: Animals; Benzoxazoles; Binding, Competitive; Brain; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lisuride; Male; Molecular Structure; Parkinson Disease; Piperazines; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Dopamine D3; Recombinant Fusion Proteins; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2006 |